Alphina Therapeutics
New Haven, US · Founded 2021 · Delaware corporation · 4 known investors
Develops therapeutics targeting altered NAD metabolism in cancer, using IP licensed from Yale University. Based in New Haven, CT.
Biotech
Founders & leadership
BF
Barbara FoxExecutive
NJ
Nicholas J GalliExecutive
KL
Kevin L. RakinExecutive
SC
Stanley ChoyExecutive
RB
Ranjit BindraNamed on SEC filing
Board
CC%20copy.jpg)
MC
AA
KR
Kevin RakinBoard director
Investors · 4
Reported raises · per SEC filings
Form D private placements$17M disclosed across 2 rounds · 2021–2026
▶$153.7KraisedMar 2026 · 3 investors · BiotechnologyRule 506(b)
▶$153.7KraisedMar 2026 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Barbara FoxExecutive Officer, Director
- Colleen CuffaroDirector
- Nicholas J GalliExecutive Officer, Director
- Kevin RakinDirector
- Matthew CohenDirector
- Ranjit BindraDirector
- Offering amount
- $10M
- Amount sold
- $153.7K
- First sale
- Feb 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$16.9MraisedSep 2021 · 19 investors · BiotechnologyRule 506(b)
▶$16.9MraisedSep 2021 · 19 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Colleen CuffaroExecutive Officer, Director
- Anurag AgarwalDirector
- Ranjit BindraExecutive Officer, Director
- Kevin L. RakinExecutive Officer, Director
- Stanley ChoyExecutive Officer
- Offering amount
- $40M
- Amount sold
- $16.9M
- First sale
- Sep 2021
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapIntellia Therapeutics10 shared keywordsIntellia Therapeutics develops in vivo and ex vivo CRISPR/Cas9 gene editing therapies aimed at treating the root causes of severe genetic diseases, with lead candidates for hereditary angioedema and ATTR amyloidosis. The company operates as a clinical-stage biopharmaceutical company pursuing potentially curative treatments from discovery through commercialization.
Bioworld10 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with Alphina Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Alphina Therapeutics do?
- Develops therapeutics targeting altered NAD metabolism in cancer, using IP licensed from Yale University. Based in New Haven, CT.
- Who are Alphina Therapeutics's investors?
- Alphina Therapeutics's investors include Canaan Partners, Connecticut Innovations, HighCape Capital, OUP (Osage University Partners).
- How much funding has Alphina Therapeutics raised?
- Alphina Therapeutics has disclosed $17M raised across 2 rounds.
- Where is Alphina Therapeutics headquartered?
- Alphina Therapeutics is headquartered in New Haven, US.